Foveolar effects of dexamethasone intravitreal implant in central retinal vein occlusion

Bikbov M.M.

GBU "Ufimskiĭ NII glaznykh bolezneĭ" AN Respubliki Bashkortostan

Gil’manshin T.R.

Ufa Eye Research Institute, 90 Pushkina St., Ufa, Russian Federation, 450008

Gilyazova I.I.

Ufa Eye Research Institute, 90 Pushkina St., Ufa, Russian Federation, 450008

Foveolar effects of dexamethasone intravitreal implant in central retinal vein occlusion

Authors:

Bikbov M.M., Gil’manshin T.R., Gilyazova I.I.

More about the authors

Journal: Russian Annals of Ophthalmology. 2016;132(2): 21‑25

DOI: 10.17116/oftalma2016132221-25

Downloaded: 14

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Bikbov MM, Gil’manshin TR, Gilyazova II. Foveolar effects of dexamethasone intravitreal implant in central retinal vein occlusion. Russian Annals of Ophthalmology. 2016;132(2):21‑25. (In Russ.)
https://doi.org/10.17116/oftalma2016132221-25

Подписка 2025 (Russian Annals of Ophthalmology)

Close metadata

Aim — to evaluate functional and morphometric parameters of the central retina in patients with postocclusive macular edema treated with dexamethasone intravitreal implant injection. Material and methods. We examined 5 patients (5 eyes) with newly diagnosed central retinal vein occlusion complicated by macular edema, including 4 men and 1 woman aged 55.8±3.65 years (experimental group). All the patients received a single injection of dexamethasone intravitreal implant. The maximum follow-up period was 12 months. The control group consisted of 5 presbiopic patients (10 eyes) aged 59.14±3.14 years. Results. One month after injection, the best corrected visual acuity (BCVA) and central retinal light sensitivity improved (from 0.09±0.03 to 0.19±0.05 and from 3.18±0.19 to 11.07±0.97 dB, correspondingly), while foveolar thickness decreased from 425.36±57.87 to 273.75±36.65 µm. One year after the treatment, BCVA remained high and averaged 0.21±0.14. The total light sensitivity also remained higher than that at baseline, however, decreased down to 4.8±0.76 dB. Optical coherence tomography showed some flatness of the fovea. Foveolar thickness appeared 1.5 times higher than that in the control group and 1.2 times higher than that at the 1-month follow-up after dexamethasone intravitreal implant injection. Over the whole follow-up period, IOP has never significantly exceeded the baseline, optical media remained clear. Conclusion. 1. Dexamethasone intravitreal implant has been shown effective in resolving postocclusive macular edema, improving visual functions, and increasing central retinal light sensitivity within the first month after injection. 2. Positive changes in morphometric parameters of the central retina induced by the injection involve inner segments of photoreceptors as well as the outer nuclear, outer plexiform and inner nuclear layers. The morphofunctional effect persists for no less than 12 months after injection. 3. Over the 1-year follow-up period, there has been no negative influence of the implant on either intraocular pressure level, or lens transparency.

Keywords:

retinal vein occlusion

dexamethasone intravitreal implant

macular edema

morphofunctional parameters

Authors:

Bikbov M.M.

GBU "Ufimskiĭ NII glaznykh bolezneĭ" AN Respubliki Bashkortostan

Gil’manshin T.R.

Ufa Eye Research Institute, 90 Pushkina St., Ufa, Russian Federation, 450008

Gilyazova I.I.

Ufa Eye Research Institute, 90 Pushkina St., Ufa, Russian Federation, 450008

List of references:

Bikbov M, Fayzrakhmanov R, Gil'manshin T, Gilyazova I. Modern tendencies of conservative treatment of retinal vein thrombosis. Kataraktal'naya i refraktsionnaya khirurgiya. 2014;3(14):11-16. (In Russ.)
Bikbov M, Fayzrakhmanov R, Gil'manshin T, Yarmukhametova A. Functional vision as a complex index of visual function in patients with ophthalmopathology. Meditsinskiy al'manakh. 2014;1(31):59-62. (In Russ.)
Katsnel'son L, Forofonova T, Bunin A. Sosudistye zabolevaniya glaz [Vascular eye diseases]. Moscow: Meditsina; 1990. (In Russ.)
Tankovskiy V. Trombozy ven setchatki [Retinal vein thrombosis]. Moscow: Voenizdat; 2000. (In Russ.)
Tul'tseva S, Astakhov Yu. Okklyuzii ven setchatki (etiologiya, patogenez, klinika, diagnostika, lechenie) [Retinal vein occlusion (etiology, pathogenesis, clinical findings, diagnosis and treatment)]. St. Petersburg: Izdatel'stvo N-L; 2010. (In Russ.)
Shadrichev F, Shklyarov E, Grigor'eva N. The usage of corticosteroids in treatment of diabetic macular edema. Oftal'mologicheskie vedomosti. 2011;4(2):76-88. (In Russ.)
Shishkin M, Perova N, Gil'manshin T, Dovzhik I. Experimental rationale for use «Kenalog» in the vitreous chamber of the eye after vitrectomy. Vestnik Natsional'nogo mediko-khirurgicheskogo tsentra im. N.I. Pirogova. 2008;3(1):43-51. (In Russ.)
Bikbov M, Fayzrakhmanov R, Yarmukhametova A. Vozrastnaya makulyarnaya degeneratsiya [Age-related macular degeneration]. Moscow: Aprel'; 2013. (In Russ.)
Bikbov M, Babushkin A, Orenburkina O. The use of anti-VEGF drugs in treatment of neovascular glaucoma. Vestnik oftal'mologii. 2012;128(5):50-53. (In Russ.)
Barkhanova A. Klinicheskaya farmakologiya glyukokortikoidov i taktika ikh primeneniya [Clinical pharmacology of glucocorticoids and tactics of usage]. Moscow: TsOLIUV; 1985. (In Russ.)
Vogralik V. Gormony i gormonal'nye preparaty v klinike vnutrennikh bolezney [Hormones and hormonal agents in clinical picture of internal diseases]. Moscow: Meditsina; 1974. (In Russ.)
Jonas JB, Degenring R, Kreissig I. Intravitreal injection of triamcinolone for diffuse macular edema. Arch Ophthalmol. 2004;122:1086-1088. doi:10.1001/archopht.122.7.1086.
Beer PM, Bakri SJ, Singh RJ. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology. 2003;110:681-686. doi:10.1016/S0161-6420(02)01969-3.
Bakri SJ, Beer PM. The effect of intravitreal triamcinolone acetonide on intraocular pressure. Ophthalm Surg Lasers and Imag. 2003;34:386-390. doi:10.3928/1542-8877-20030901-08.
Park СH, Jaffe GJ, Fekrat S. Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion. Am J Ophthalmol. 2003;136:419-425. doi:10.1016/S0002-9394(03)00228-9.
Mayer WJ, Wolf A, Kernt M, Kook D, Kampik A, Ulbig M, Haritoglou C. Twelwe-month experience with Ozurdex for the treatment of macular edema associated with retinal vein occlusion. Eye. 2013;27:816-822. doi:10.1038/eye.2013.79.
Belyy Yu, Novikov S, Tereshchenko A, Kolesnik A. Delivery mechanisms of medications to structures of posterior eye segment. Kataraktal'naya i refraktsionnaya khirurgiya. 2014;14(2):10-14. (In Russ.)

Close metadata